Watch the Catalyst Calendar Replay for a Limited Time Only

That was CRAZY! That was CRAZY! Topline Trader: Topline Trader That was CRAZY! We recently taught thousands of people all the details of the trading strategy that’s been finding up to three double- and triple-digit trade opportunities every week! If you weren’t able to make it to our webinar, I understand. But you’re in luck! Because you can [watch the replay right now.]( But warning: I’m only keeping this up for a short while longer. I can only teach so many people how I’ve been finding trades like a 225% win on Intra-Cellular Therapies… A 77% gain on Evoke Pharma… Or a 171% payday on Aurinia Pharmaceuticals. If I teach too many folks how to do it, the trades will get too heavy. So if you are at all interested in learning how YOU could get set up for 12 potentially HUGE biotech trades over the next month (and up to 144 over the course of the next year)… You need to [watch the replay right now]( before it gets taken down. [Click here to check it out.]( Sincerely, [keith-kohl-signature-transparent] Keith Kohl Investment Director, Catalyst Calendar --------------------------------------------------------------- If you no longer wish to receive updates from Catalyst Calendar you [may opt out here.]( Catalyst Calendar, Copyright © 2021, Angel Publishing, LLC., 3 E. Read Street, Baltimore, MD 21202. For customer service, please call 877-303-4529. All rights reserved. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. Angel Publishing and Catalyst Calendar do not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. The publisher, editors, and consultants of Angel Publishing may actively trade in the investments discussed in this newsletter. They may have substantial positions in the securities recommended and may increase or decrease such positions without notice. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question. Unauthorized reproduction of this newsletter or its contents by xerography, facsimile, or any other means is illegal and punishable by law.